The diagnostic value of HPV detection in squamous cell carcinoma of cervical lymph node metastasis from an unknown primary site (with report of 6 cases)
Jiang Chenxue1, Xu Tingting1, Wang Cuihong2, Sun Guohua3, Wang Qifeng4, Shen Chunying1, Hu Chaosu1, Lu Xueguan1
1Departmentof Radiation Oncology Fudan University Shanghai Cancer Center,Shanghai 200032,China; 2Department of Radiology Fudan University Shanghai Cancer Center,Shanghai 200032,China; 3Department of Surgery of Head & NeckFudan University Shanghai Cancer Center,Shanghai 200032,China; 4Department of Pathology Fudan University Shanghai Cancer Center,Shanghai 200032,China
Abstract:Objective To evaluate the diagnostic value of HPV detection in squamous cell carcinoma of the cervical lymph node metastasis from an unknown primary site. Methods Clinical data of 6 patients who were initially diagnosed with squamous cell carcinoma of the cervical lymph node metastasis from an unknown primary site and eventually diagnosed with HPV-related oropharyngeal squamous cell carcinoma were collected,and the process of diagnosis was analyzed. Results Upon the initial admission,all patients were diagnosed with squamous cell carcinoma of the cervical lymph node metastasis with positive p16 expression,positive HPV-16 subtype and negative EBER expression. No obvious primary lesion was found after comprehensive examination. Subsequently,four of them underwent ipsilateral tonsollar blind biopsy (n=2) and ipsilateral tonsillectomy (n=2). All these four patients were pathologically diagnosed with tonsillar squamous cell carcinoma. For the other two cases,MRI detected the thickening complicated with enhancement of ipsilateral wall of oropharynx and tongue root after follow-up for D149 and D545,respectively. Biopsy confirmed the diagnosis of squamous cell carcinoma of the tonsil and tongue root,respectively. Conclusion For patients with HPV-positive squamous cell carcinoma of the cervical lymph node metastasis from an unknown primary site,the possibility that the primary lesion originates from the oropharyngeal site,especially the tonsil and tongue root,should be highly suspected.
Jiang Chenxue,Xu Tingting,Wang Cuihong et al. The diagnostic value of HPV detection in squamous cell carcinoma of cervical lymph node metastasis from an unknown primary site (with report of 6 cases)[J]. Chinese Journal of Radiation Oncology, 2020, 29(4): 259-261.
[1] Cheraghlou S,Torabi SJ,Husain ZA,et al. HPV status in unknown primary head and neck cancer:prognosis and treatment outcomes[J]. Laryngoscope, 2019,129(3):684-691. DOI:10.1002/lary.27475. [2] Grau C,Johansen LV,Jakobsen J,et al. Cervical lymph node metastases from unknown primary tumours:results from a national survey by the Danish Society for Head and Neck Oncology[J]. Radiother Oncol,2000,55(2):121-129. DOI:10.1016/S0167-8140(00)00172-9. [3] 陆雪官,冯炎,胡超苏,等.60例原发灶不明的颈转移性鳞癌的放射治疗[J]. 中华放射肿瘤学杂志,2001,10(4):246-249. DOI:10.3760/j.issn:1004-4221.2001.04.009. [4] D′souza G,Westra WH,Wang SJ,et al. Differences in the prevalence of human papillomavirus (HPV) in head and neck squamous cell cancers by sex,race,anatomic tumor site,and HPV detection method human papillomavirus prevalence in head and neck squamous cell cancers[J]. JAMA Oncol,2017,3(2):169-177. DOI:10.1001/jamaoncol.2016.3067. [5] Motz K,Qualliotine JR,Rettig E,et al. Changes in unknown primary squamous cell carcinoma of the head and neck at initial presentation in the era of human papillomavirus[J]. JAMA Otolaryngol Head Neck Surg,2016,142(3):223-228. DOI:10.1001/jamaoto.2015.3228. [6] Gregoire V,Ang K,Budach W,et al. Delineation of the neck nodelevels for head and neck tumors:a 2013 update. DAHANCA, EORTC,HKNPCSG,NCIC CTG,NCRI,RTOG,TROG consensus guidelines[J]. Radiother Oncol,2014,110(1):172-181. DOI:10.1016/j.radonc.2013.10.010. [7] Galloway TJ,Ridge JA. Management of squamous cancer metastatic to cervical nodes with an unknown primary site[J]. J Clin Oncol,2015,33(29):3328-3337. DOI:10.1200/jco.2015.61.0063. [8] Ryan JF,Motz KM,Rooper LM,et al. The Impact of a stepwise approach to primary tumor detection in squamous cell carcinoma of the neck with unknown primary[J]. Laryngoscope, 2019,129(7):1610-1616. DOI:10.1002/lary.27625. [9] Cianchetti M,Mancuso AA,Amdur RJ,et al. Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site[J]. Laryngoscope,2009,119(12):2348-2354. DOI:10.1002/lary.20638. [10] Kothari P,Randhawa PS,Farrell R. Role of tonsillectomy in the search for a squamous cell carcinoma from an unknown primary in the head and neck[J]. Brit J Oral Maxillofacial Surg,2008,46(4):283-287. DOI:10.1016/j.bjoms.2007.11.017. [11] Di Maio P,Iocca O,De Virgilio A,et al. Role of palatine tonsillectomy in the diagnostic workup of head and neck squamous cell carcinoma of unknown primary origin:a systematic review and meta-analysis[J]. Head Neck,2018,41(4):1112-1121. DOI:10.1002/hed.25522. [12] Kreimer AR,Clifford GM,Boyle P,et al. Human papillomavirus types in head and neck squamous cell carcinomas worldwide:a systematic review[J]. Cancer Epidemiol Biomark Prevent,2005,14(2):467-475. DOI:10.1158/1055-9965.epi-04-0551. [13] Parkin DM,Bray F. The burden of HPV-related cancers[J]. Vaccine,2006,24(Suppl 3):11-25. DOI:10.1016/j.vaccine.2006.05.111. [14] Ruuskanen M,Irjala H,Minn H,et al. Epstein-Barr virus and human papillomaviruses as favorable prognostic factors in nasopharyngeal carcinoma:a nationwide study in finland[J]. Head Neck,2018,41(2):349-357. DOI:10.1002/hed.25450. [15] Deng Z,Uehara T,Maeda H,et al. Epstein-Barr virus and human papillomavirus infections and genotype distribution in head and neck cancers[J]. PLoS One,2014,9(11):e113702. DOI:10.1371/journal.pone.0113702. [16] Lewis JS,Beadle B,Bishop JA,et al. Human papillomavirus testing in head and neck carcinomas:guideline from the college of American pathologists[J]. Arch Pathol Lab Med,2018,142(5):559-597. DOI:10.5858/arpa.2017-0286-CP. [17] Fakhry C,Lacchetti C,Perez-ordonez B. Human papillomavirus testing in head and neck carcinomas:ASCO clinical practice guideline endorsement summary of the CAP guideline[J]. J Oncol Prac,2018,14(10):613-617. DOI:10.1200/jop.18.00433.